The MDx market, will grow to $4 billion by the end of the decade, according to a market study announced today by Boston based TSG Partners, a specialty advisory group that combines corporate strategy and corporate finance. The study covers detection of DNA variation or RNA expression with the intent to diagnose disease, determine a patient's susceptibility to disease, or determine the prognosis of condition.
PharmacoGenomicsonline.com (http://www.pharmacogenomicsonline.com/index.aspx?ID=71636)
